The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of radium-223 in bone-metastatic prostate cancer patients with and without homologous repair deficiency (HRD) mutations.
 
Pedro Henrique Isaacsson Velho
No Relationships to Disclose
 
Fahad Qazi
No Relationships to Disclose
 
Sayeedul Hasan
No Relationships to Disclose
 
Michael Anthony Carducci
Consulting or Advisory Role - Abbvie; Astellas Pharma; Churchill Pharmaceuticals; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); pfizer (Inst)
 
Mario A. Eisenberger
Honoraria - pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen; pfizer; Sanofi; Sanofi
Research Funding - Genentech; Sanofi; Tokai Pharmaceuticals
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Pfizer; Sanofi
 
Phuoc T. Tran
Consulting or Advisory Role - Astellas Pharma; Dendreon; GenomeDx; Reflexion Medical; Regeneron
Research Funding - Astellas Pharma (Inst); Reflexion Medical (Inst)
Patents, Royalties, Other Intellectual Property - Compounds and Methods of Use in Ablative Radiotherapy. Patent filed 3/9/2012. PCT/US2012/028475. PCT/WO/2012/122471.
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi